Oncolytics presents REO 033 in-progress abstract at ESMO 2026
The company is displaying data from its study of pelareorep in colorectal cancer at the annual ESMO conference. Positive results from a previous trial support accelerated approval potential for this regulatory pathway.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed